SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

SCLN 7.78 +0.21 (2.77%)
price chart
SciClone To Present At Two Investor Conferences On September 10, 2015
FOSTER CITY, Calif., Aug. 27, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at two investor conferences ...
SciClone Pharmaceuticals, Inc. Short Interest Update  American Trade Journal
Gl Partners Capital Management Ltd Bought Sciclone Pharmaceuticals Inc's Shares
Gl Partners Capital Management Ltd has filled a SC 13D/A form regarding Sciclone Pharmaceuticals Inc 8.06 +0.04 0.50% . Filing Link: 000114420415051156.
SciClone Pharmaceuticals, Inc. Price Target Update  News Watch International
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Price Target Update
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN): According to 2 Analysts, The short term target price has been estimated at $ 11.25.
SciClone Pharmaceuticals Cut to "Hold" at Zacks (SCLN)  Dakota Financial News
The Insider Friedhelm Blobel Sold 10000 shares of SciClone Pharmaceuticals ...
The President & CEO of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) 8.06 +0.04 0.50% , Friedhelm Blobel has made a surprising trade in the California-based company that is worth $91,515 US Dollars.
SciClone Pharmaceuticals, Inc. (SCLN:NASDAQ) Analyst Price Target Update  News Watch International
Short Interest Update on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has seen a shortfall of 95,022 shares or 2.5% in the short interest. The remaining shorts are 8.1% of the total floated shares.
Sciclone Pharmaceuticals Inc (SCLN) Discloses Form 4 Insider Selling : Exec ...  American Trade Journal
Why SciClone Pharmaceuticals, Inc. Is Surging Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Friedhelm Blobel Sold 10000 shares of SciClone Pharmaceuticals, Inc. (NASDAQ ...
It was announced in a public form submitted to the U.S. SEC that Friedhelm Blobel, who works for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) , and is currently the President & CEO completed an insider transaction on July 27, 2015. Friedhelm unloaded ...
Zacks Rating on SciClone Pharmaceuticals, Inc.  News Watch International
Insider Selling: Friedhelm Blobel Sells 10000 Shares of SciClone ...  sleekmoney
Sciclone Pharmaceuticals Inc Gl Partners Capital Management Ltd increased Position
Gl Partners Capital Management Ltd has filled a SC 13D/A form regarding Sciclone Pharmaceuticals Inc 8.06 +0.04 0.50% . Filing Link: 000114420415050226.
SciClone Pharmaceuticals, Inc. Analyst Rating Update  American Trade Journal
SciClone Pharmaceuticals Lowered to "Hold" at Zacks (SCLN)  Mideast Time
SciClone Pharmaceuticals Inc. (SCLN) Drops 9.93% on August 24
SciClone Pharmaceuticals Inc. (SCLN) was one of the Russell 2000's biggest losers for Monday August 24 as the stock slid 9.93% to $7.26, a loss of $-0.8 per share.
Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Drops by -1.35%
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has lost 1.35% during the past week and dropped 16.65% in the last 4 weeks.
Can't Ignore: SciClone Pharmaceuticals (NASDAQ:SCLN), Trecora Resources ...  Property Mentor